Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.96 USD | -0.78% | +6.46% | -14.59% |
05-09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
05-09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.59% | 2.52B | |
+33.01% | 50.85B | |
+1.06% | 42.82B | |
+48.94% | 42.03B | |
-4.22% | 29.55B | |
+11.05% | 26.11B | |
-21.57% | 19.13B | |
+8.35% | 13.05B | |
+27.33% | 12.16B | |
+23.45% | 12.08B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- JPMorgan Cuts Intellia Therapeutics' Price Target to $79 From $82, Keeps Overweight Rating